October 18, 2026 Page

CURRENT AND PROJECTED ACCRUAL¹

BY SWOG AND NON-SWOG INSTITUTIONS

TO SWOG-COORDINATED NCTN TRIALS

BY COMMITTEE

80% of Calendar Year is Past

Committee Annual
Base
Accrual²		 Projected
2026
Accrual		 2026
Projected
Percentage
of Base Accrual		 2026
Accrual
to date		 Projected
Increase
<Decrease>
from Base		 Accrual
Last
12 Months
BREAST 472 1016 214% 807 544 985
ERLYTX 54 60 111% 48 6 59
GI 100 94 94% 75 -6 93
GU 256 298 116% 237 42 295
LEUK 354 763 215% 606 409 744
LUNG 817 549 67% 436 -268 546
LYMPH 181 373 205% 296 192 353
MELAN 364 0 0% 0 -364 0
MMYEL 192 108 56% 86 -84 102
MULT 25 43 171% 34 18 48
Total 2815 3304   2625 489 3225

¹ Includes Accrual to Screen Only Studies

² Average Annual Accrual Over Three Prior Calendar Years

October 18, 2026 Page

CURRENT AND PROJECTED ACCRUAL¹

BY SWOG AND NON-SWOG INSTITUTIONS

TO SWOG-COORDINATED NCORP TRIALS

BY COMMITTEE

80% of Calendar Year is Past

Committee Annual
Base
Accrual²		 Projected
2026
Accrual		 2026
Projected
Percentage
of Base Accrual		 2026
Accrual
to date		 Projected
Increase
<Decrease>
from Base		 Accrual
Last
12 Months
CCD 578 209 36% 166 -369 195
PEOLC 52 29 55% 23 -23 59
PREV 169 0 0% 0 -169 0
SXQOL 958 593 62% 471 -365 584
Total 1757 831   660 -926 838

¹ Includes Accrual to Screen Only Studies

² Average Annual Accrual Over Three Prior Calendar Years

October 18, 2026 Page

CURRENT AND PROJECTED ACCRUAL

BY SWOG AND NON-SWOG INSTITUTIONS

TO SWOG CTP TRIALS

BY STUDY

80% of Calendar Year is Past

Committee Study Projected
2026
Accrual		 2026
Accrual
to date		 Accrual
Last
12 Months
ERLYTX 21CTP.HN01 14 11 11
LEUK 21CTP.LEUK01 10 8 8
Total   24 19 19

¹ Includes Accrual to Screen Only Studies

² Average Annual Accrual Over Three Prior Calendar Years

October 18, 2026 Page

CURRENT AND PROJECTED ACCRUAL¹

BY SWOG INSTITUTIONS

TO ANY NCTN TRIAL

BY COMMITTEE

80% of Calendar Year is Past

Committee Annual Base Accrual² Projected
2026
Accrual		 2026
Projected
Percentage
of Base Accrual		 2026
Accrual
to date		 Projected
Increase
<Decrease>
from Base		 Accrual
Last
12 Months
BREAST 352 694 197% 551 342 698
ERLYTX 42 45 107% 36 3 44
GI 157 128 81% 102 -29 123
GU 399 305 76% 242 -94 301
LEUK 182 342 188% 272 160 342
LUNG 551 357 65% 284 -194 354
LYMPH 173 292 168% 232 119 279
MELAN 228 8 3% 6 -220 8
MMYEL 135 70 52% 56 -65 65
MULT 14 19 138% 15 5 19
OTHER 57 63 110% 50 6 60
Total 2290 2323   1846 33 2293

¹ Includes Accrual to Screen Only Studies

² Average Annual Accrual Over Three Prior Calendar Years

October 18, 2026 Page

CURRENT AND PROJECTED ACCRUAL¹

BY SWOG INSTITUTIONS

TO ANY NCORP TRIAL

BY COMMITTEE

80% of Calendar Year is Past

Committee Annual Base Accrual² Projected
2026
Accrual		 2026
Projected
Percentage
of Base Accrual		 2026
Accrual
to date		 Projected
Increase
<Decrease>
from Base		 Accrual
Last
12 Months
CCD 534 162 30% 129 -372 158
GI 0 1 .% 1 1 1
PEOLC 37 26 71% 21 -11 50
PREV 341 224 65% 178 -117 231
SXQOL 665 487 73% 387 -178 474
Total 1577 900   716 -677 914

¹ Includes Accrual to Screen Only Studies

² Average Annual Accrual Over Three Prior Calendar Years

October 18, 2026 Page

SWOG OPEN AND TEMPORARILY CLOSED NCTN STUDIES

Comm. Phase Study Open
Date		 Months
Open		 Total
Regs		 Accrual
Goal		 Monthly
Accrual
Rate		 Date of
Expected Closure or
Temporary Closure		 Proj.
Study
Duration
(Years)
BREAST III S2206: Brst, Stg II-III, MP2, Neoadj Chemo +/- Durva 10/30/2023 35 426 960 11.5 Aug-2030 6.8
    S2212: Breast, TNBC, Neoadj Chemo + Pembro 07/21/2023 38 1747 2400 70.0 Jul-2027 4.0
    S2511: Brst, de novo StgIV oligo, locoreg tx vs SOC 08/18/2026 2 0 534      
ERLYTX II SN2426: cSCC, IC Met/Inop, Amivantamab v Cetuximab 01/28/2026 8 11 86 1.3 Jun-2031 5.4
  II-III S2012: Extrapulm NEC, Stg IV, Combo Chemo +/- Atezo 12/02/2021 58 170 189 3.5 Mar-2027 5.3
  III S2505: Sarcoma, Stg II-IIIB, Surg + Short vs Std RT 07/06/2026 3 0 296 0.3 > 15 Yrs > 15 Yrs
GI II S2104: Panc,Resect High-risk,Postop Adj Chemo vs Obs 10/14/2021 60 111 154 2.8 Jan-2028 6.3
  II-III S2303: Gas/Esoph/GEJ, Adv, Ram + Pac +/- Nivo 05/06/2024 29 121 224 5.0 Jun-2028 4.1
  III S2433: PANC, KRAS WT, Met, SOC Chemo +/- Panitumumab 12/26/2025 9 1 94 0.2 > 15 Yrs > 15 Yrs
GU II S2210: Pros, High Risk, BRCA, Neoadj Carbo 08/14/2023 38 7 44 0.2 > 15 Yrs > 15 Yrs
    S2427: Blad, MIBC, RT + Pembrolizumab 09/04/2025 13 60 111 8.3 Apr-2027 1.6
  III S1802: Pros, Stg IV, SST ± Surg/RT to Primary Tum 09/17/2018 97 1060 1273 7.7 Jan-2029 10.3
    S1931: RENAL, Stg IV, IO + Nephrectomy. vs IO Only 11/16/2020 71 164 336 2.5 Jun-2032 11.6
    S2312: Pros, MCRPC, Cab +/- Carb 09/03/2024 25 75 500 4.2 Apr-2035 10.6
    S2419: Renal, adv clear cell, IO +/- Biotx, BIOFRONT 04/22/2026 5 40 718 6.8 Jan-2035 8.7
LEUK II MM1OA-S03: AML, Newly Dx, Ven+ASTX727 vs Ven+ASTX727+Ena 04/01/2025 18 30 102 3.7 May-2028 3.1
    MM1OA-S04: MyeloMATCH: AML, ASTX727 + Ven (28D v 14D) 07/22/2026 2 1 126      
    MM1YA-S01: AML, High Risk, Age <60, 7+3 vs experimental 05/16/2024 29 94 335 4.2 Jul-2031 7.2
    S2507: ALL/ALAL, KMT2A-trans, Blina +/- Revumenib 09/22/2026 0 0 90      
  III S1925: CLL/SLL, Newly Dx HR, Early vs Delayed V+O 12/14/2020 70 212 247 5.0 May-2027 6.4
    S2504: Richter Trans., Untreated, R-CHOP +/- Pirto 06/01/2026 4 2 102 0.4 > 15 Yrs > 15 Yrs
  OTHER MYELOMATCH: MSRP for the NCI myeloMATCH Clinical Trials 05/16/2024 29 1362   53.0 .- . .
LUNG II S1900G: EGFR-Mut, MET-Amp: Capmat + Osimert +/- Ramu 04/03/2023 42 28 44 0.5 Jun-2029 6.2
    S1900K: MET Exon 14: Tepotinib +/- Ramucirumab 12/18/2023 34 31 56 1.0 Nov-2028 4.9
    S1900N: AGAs: SG alone, I alone, or SG + I 08/03/2026 2 1 117      
    S2409: ESCLC, Durvalumab +/- Biomarker Directed Tx 09/08/2025 13 18 900 2.3 > 15 Yrs > 15 Yrs
  II-III S1800E: Non-Match: Docetaxel + Ramu +/- Cemiplimab 04/28/2025 17 144 378 9.2 Nov-2028 3.6
  III S2414: NSCLC, Stg II-IIIB, Durva vs Surveillance 03/14/2025 19 15 306 1.2 > 15 Yrs > 15 Yrs
  OTHER LUNGMAP: NSCLC, Adv, Master 01/28/2019 92 4149   28.3 .- . .
LYMPH II S2114: NHL, Rel/Ref, CD19 CAR-T +/- Consolidation 02/23/2023 43 256 396 7.7 Apr-2028 5.1
    S2207: LBCL, Transplant Inelig, Targeted Tx + Tafa 06/30/2023 39 43 173 0.7 > 15 Yrs > 15 Yrs
    S2506: NHL, R/R MZL, Mozun +/- Zanu or Pola 08/18/2026 2 1 138      
  III S2308: FL, LTB, Mosunetuzumab vs Rituximab 08/01/2024 26 445 600 24.0 Apr-2027 2.7
MMYEL II S2005: WM, Prev. Untreated, I/R or Z v V/R 06/24/2021 63 45 92 3.3 Dec-2027 6.5
  III S1803: MM, Maintenance, Len vs Len/Dara 06/27/2019 87 1338 1100 0.0    
    S2209: MM, Newly Dx, VRd-R->R v DRd-R->R v DRD-DR->D 05/30/2023 40 149 510 3.5 May-2035 12.0
    S2213: AL Amyloidosis, Newly Dx, Dara-VCD v ASCT 12/01/2023 34 55 142 2.3 Nov-2029 6.0
MULT II S2101: Melan or HNSCC, Adv, Cabo + Nivo 10/14/2022 48 110 220 3.3 Jul-2029 6.8
 
Accrual goals assume studies are not terminated early as a result of interim analysis.
Studies may have accrual objectives specific to subsets of patients and are not reflected in this report.
Monthly accrual rate is projected from accrual in the previous six months for studies open at least three months.
Expected closure dates are calculated for SWOG coordinated studies that have been open at least three months.

October 18, 2026 Page

SWOG OPEN AND TEMPORARILY CLOSED NCORP STUDIES

Comm. Phase Study Open
Date		 Months
Open		 Total
Regs		 Accrual
Goal		 Monthly
Accrual
Rate		 Date of
Expected Closure or
Temporary Closure		 Proj.
Study
Duration
(Years)
CCD III S1703: Met Breast, STM-monitoring v Usual Care 07/16/2018 99 477 498 3.7 Mar-2027 8.7
    S2417CD: Colrec Surv, Follow-up w/ CTAC site 08/04/2025 14 140 654 13.5 Dec-2029 4.4
    S2424CD: A-PACT vs SOC for GOC communication 06/01/2026 4 8 1000 1.8 > 15 Yrs > 15 Yrs
PEOLC III S1501: Breast Stg IV, Card Tox Obs and w/ Carvedilol 09/15/2017 109 402 491 2.2 Mar-2030 12.5
    S2408: Panc Fistula Prevention, Lanreotide 02/14/2025   63 274      
SXQOL III S2205: ICE COMPRESS: Reduction of CIPN from Taxanes 03/16/2023 43 687 777 15.7 Mar-2027 4.0
  OTHER S2013: I-CHECKIT: ICI toxicity risk prediction study 08/16/2021 62 2668 3609 32.7 Feb-2029 7.5
 
Accrual goals assume studies are not terminated early as a result of interim analysis.
Studies may have accrual objectives specific to subsets of patients and are not reflected in this report.
Monthly accrual rate is projected from accrual in the previous six months for studies open at least three months.
Expected closure dates are calculated for SWOG coordinated studies that have been open at least three months.

October 18, 2026 Page

SWOG OPEN AND TEMPORARILY CLOSED CTP STUDIES

Comm. Phase Study Open
Date		 Months
Open		 Total
Regs		 Accrual
Goal		 Monthly
Accrual
Rate		 Date of
Expected Closure or
Temporary Closure		 Proj.
Study
Duration
(Years)
ERLYTX II 21CTP.HN01: HN, Recur/Met, Amivantamab + Chemo 03/05/2026 7 11 50 1.5 Dec-2028 2.8
LEUK II 21CTP.LEUK01: ALL, Ph+, Asciminib, Dasatinib and Prednisone 12/11/2025 10 8 55 1.2 Feb-2030 4.2
 
Accrual goals assume studies are not terminated early as a result of interim analysis.
Studies may have accrual objectives specific to subsets of patients and are not reflected in this report.
Monthly accrual rate is projected from accrual in the previous six months for studies open at least three months.
Expected closure dates are calculated for SWOG coordinated studies that have been open at least three months.